Literature DB >> 968355

Cyclophosphamide, gold and penicillamine--disease-modifying drugs in rheumatoid arthritis--tailored dosage and ultimate success.

J M Gumpel.   

Abstract

Gold appears to be the disease-modifying drug of first choice for two reasons: response and absence of long-term toxicity. Although cyclophosphamide produces results as good or better than gold, the possible long-term toxicity outweighs the clinical benefit except in the unusual case. Penicillamine appears to be an acceptable drug of second choice.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 968355     DOI: 10.1093/rheumatology/15.3.217

Source DB:  PubMed          Journal:  Rheumatol Rehabil        ISSN: 0300-3396


  8 in total

1.  Oral gold for rheumatoid arthritis.

Authors:  J M Gumpel
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-17

2.  Corneal chrysiasis and clinical improvement with chrysotherapy in rheumatoid arthritis.

Authors:  P J Prouse; J J Kanski; J M Gumpel
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

3.  Rheumatoid arthritis.

Authors:  J M Gumpel
Journal:  Br Med J       Date:  1978-10-14

4.  Fifty years of gold in rheumatoid arthritis.

Authors: 
Journal:  Br Med J       Date:  1979-02-03

5.  Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods.

Authors:  R D Situnayake; K A Grindulis; B McConkey
Journal:  Ann Rheum Dis       Date:  1987-03       Impact factor: 19.103

6.  Age and arthritis.

Authors:  G Holden
Journal:  J R Soc Med       Date:  1982-06       Impact factor: 18.000

7.  A history of the term "DMARD".

Authors:  Jonas Kure Buer
Journal:  Inflammopharmacology       Date:  2015-05-23       Impact factor: 4.473

Review 8.  To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology.

Authors:  Jonas Kure Buer
Journal:  Inflammopharmacology       Date:  2017-02-13       Impact factor: 4.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.